MDS & AML

expert roundtables

by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD

Actionable mutations now allow for a more individualized approach to the treatment of acute myeloid leukemia (AML) than in the past. Further, patie......READ MORE

patient care perspectives

by Guillermo Garcia-Manero, MD

Advancements in uncovering the underlying pathogenesis of myelodysplastic syndrome (MDS) have led to the development of investigational therapies f......READ MORE

patient care perspectives

by Guillermo Garcia-Manero, MD

The US Food and Drug Administration approval of lower-intensity treatments, including hypomethylating agents (HMAs) and targeted and/or immunomodul......READ MORE

clinical topic updates

by Harry Paul Erba, MD, PhD

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are part of a disease spectrum that is beginning to enter into the precision medici......READ MORE

clinical topic updates

by David Sallman, MD

Mutations in FLT3 and IDH1/IDH2 are among those that are currently actionable in acute myeloid leukemia (AML). Trials of novel agents and combinati......READ MORE